ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1043

Identification of Putative Biomarkers and Molecular Mechanisms Associated with Adverse Tissue Reactions to Metal-on-Metal and Modular Neck Hip Implants

Ed Purdue1, Gabrielle Wilner2, Kritti Kolatat2, Geoffrey H. Westrich3, Friedrich Boettner4, Seth Jerabek4 and Steven R. Goldring5, 1535 East 70th Street, Hospital for Special Surgery, New York, NY, 2Research, Hospital for Special Surgery, New York, NY, 3Orthopedics, Hospital for Special Surgery, New York, NY, 4Orthopaedics, Hospital for Special Surgery, New York, NY, 5Hospital for Special Surgery, New York, NY

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: chemokines and inflammation, Hip

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose Total hip replacement (THR) is a highly successful treatment for degenerative arthritis, alleviating pain and restoring joint function in the vast majority of patients. However, inflammatory reactions to polyethylene wear debris resulting in destruction of bone (osteolysis) can lead to implant loosening and revision surgery.  To avoid the adverse effects of polyethylene wear products, metal-on-metal bearings were introduced. Recent studies, however, have revealed an alarming rate of early revision surgery related to the development of adverse local tissue reactions (ALTR) characterized by extensive and rapid necrosis of soft tissue surrounding implants with metal-on-metal (MoM) or dual modular neck (DMN) designs. We have used chemokine/cytokine profiling of synovial fluid and serum and gene expression analysis of peri-implant tissue to identify biomarkers for early detection and to gain insights into the pathogenesis of ALTR.

Methods Synovial fluid and serum was collected from ALTR and osteolysis patients at revision surgery, and cell-free aliquots were prepared and immediately frozen. Antibody arrays were used to identify selected chemokines and cytokines, and results confirmed by ELISA. For gene expression profiling, total RNA was prepared from peri-implant tissue using Trizol. RNA integrity was verified using an Agilent Bioanalyzer, and then subjected to microarray analysis (Affymetrix U133 2.0). Results were verified using real time PCR.

Results  Synovial fluid from ALTR patients demonstrated elevated levels of several chemokines and cytokines compared to those seen in osteolysis patients, including the interferon gamma inducible chemokines MIG/CXCL-9 and IP-10/CXCL10. Levels of these factors were generally higher in the DMN ALTR patients than the MoM ALTR patients. More modest elevations of these chemokines were found in ALTR serum samples. Microarray analysis revealed a unique ALTR gene expression profile that was absent in arrays prepared from peri-implant tissues from patients with osteolysis. Pathway analysis identified a unique chemokine/interferon signature that mirrored the protein profile of synovial fluid.

 

Protein

Osteolysis

ALTR – DMN

p-value (DMN)

ALTR – MOM

p-value (MoM)

Synovial Fluid

MIG

1,320 (1,901)

178,442 (120,107)

8.46 E-6

68,609 (68,867)

2.52 E-3

IP-10

1,880 (4,304)

100,137 (78,158)

9.32 E-5

32,829 (30,575)

2.00 E-3

IL-6

497 (786)

28,583 (28,481)

1.53 E-3

16,102 (21,768)

2.10 E-2

IL-8

8,621(12,820)

64,172 (58,125)

2.21 E-3

54,338 (41,930)

1.32 E-3

 

 

 

 

 

 

 

Serum

MIG

273 (163)

592 (315)

1.68 E-3

456 (279)

0.036

IP-10

17.4 (9.8)

25.7 (29.5)

0.31

32.9 (31.0)

0.074

Table 1 Mean (Standard Deviation) levels of selected proteins in the synovial fluid and serum (in pg/ml). p-values are for comparison to the osteolysis group.

Conclusion Expression profiling of peri-implant tissues from ALTR patients reveals a unique chemokine/cytokine gene signature. The corresponding gene products are detectible in synovial fluid and serum, indicating their potential utility as biomarkers for early diagnosis and monitoring of patients at risk for ALTR. In addition, pathway analysis reveals up-regulation of genes involved in lymphocyte trafficking and activation, providing insights into disease pathogenesis and importantly identifies potential therapeutic targets to prevent this devastating complication.


Disclosure:

E. Purdue,
None;

G. Wilner,
None;

K. Kolatat,
None;

G. H. Westrich,

STryker Orthopedics,

5;

F. Boettner,

Ortho Development Inc,

5,

Ortho Development Inc,

7,

Smith & Nephew, Inc.,

2,

Smith & Nephew, Inc.,

5;

S. Jerabek,

Stryker Mako,

5;

S. R. Goldring,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-putative-biomarkers-and-molecular-mechanisms-associated-with-adverse-tissue-reactions-to-metal-on-metal-and-modular-neck-hip-implants/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology